Optimizing anti-TNF treatments in inflammatory bowel disease
Top Cited Papers
- 1 January 2014
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 13 (1), 24-30
- https://doi.org/10.1016/j.autrev.2013.06.002
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBDAlimentary Pharmacology & Therapeutics, 2012
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewThe American Journal of Gastroenterology, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Review: Predicting response to anti-TNF agents for the treatment of Crohn's diseaseTherapeutic Advances in Gastroenterology, 2009
- Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab‐treated and naïve patientsAlimentary Pharmacology & Therapeutics, 2008
- The use of adalimumab in the management of refractory Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2007
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's diseaseGut, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus MonkeysThe Journal of pharmacology and experimental therapeutics, 2005
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002